Key result
Transcatheter aortic valve implantation in elderly patients was associated with incremental increases in quality of life VAS scores over 12 months and a 12-month all-cause mortality of 17.8%.
Why the study?
Does transcatheter aortic valve implantation (TAVI) improve quality of life and all-cause mortality in elderly patients at 12 months?
Cohort (n=101)
Does transcatheter aortic valve implantation (TAVI) improve quality of life and all-cause mortality in elderly patients at 12 months?
TAVI significantly improves overall quality of life, specifically mobility and anxiety, in elderly patients at 12 months, with transfemoral access offering better early quality of life compared to non-transfemoral access.
Answers are grounded in this paper and cite their sources.
TAVI may support QoL consideration in elderly patients; leaves open randomized confirmation of benefits versus alternatives.
PURPOSE: Restoration of quality of life (QoL) and improvement of clinical outcomes is crucial in elderly patients undergoing transcatheter aortic valve implantation (TAVI). We sought to evaluate changes in QoL and all-cause mortality 12 months after TAVI. METHODS: A total of 101 patients who underwent TAVI were included. Patients were followed for 12 months. QoL was assessed at baseline and at 1, 6 and 12 months after TAVI using EQ-5D-3L with a visual analog scale (VAS). RESULTS: Patients who reported some problems with mobility at baseline showed better mobility after 12 months (p = 0.001). On the other hand, those who reported issues with self-care, usual activity or pain did not show significant improvement (p = 0.41; p = 0.12; p = 0.27, respectively). Patients reporting anxiety at baseline improved 12 months later (p = 0.003). VAS score showed an incremental increase during follow-up (p<0.001). Transfemoral access was associated with higher VAS score values after 1 month (median (IQR): 65.0 (50.0-75.0) vs. 54.0 (50.0-60.0); p = 0.019) but not after 12 months (70.0 (62.5-80.0) vs. 67.5 (55.0-70.0); p = 0.07) as compared to non-transfemoral access. In multivariable regression analysis, only age and the presence of coronary chronic total occlusion were independently associated with VAS score at 12 months. In-hospital, 1-, 6- and 12-month mortality rates were 6.9%, 10.9%, 15.8 and 17.8%, respectively. CONCLUSIONS: TAVI provides improved QoL with relatively good clinical outcomes. However, not all components of QoL may be improved. Patients treated with transfemoral access might have better QoL than those who had non-transfemoral access, especially early after TAVI.
No takes yet. Share an insight, caveat, or question.
Kleczyński et al. (2016) conducted a cohort in Elderly patients undergoing transcatheter aortic valve implantation (TAVI) (n=101). Transcatheter aortic valve implantation (TAVI) was evaluated on Changes in quality of life (VAS score) and all-cause mortality at 12 months (p=<0.001). Transcatheter aortic valve implantation in elderly patients was associated with incremental increases in quality of life VAS scores over 12 months and a 12-month all-cause mortality of 17.8%.
Synapse has enriched 10 related papers. Consider them for comparative context: